Sentiment Behind FDA Approval of Alexza's (ALXA) Adusave Improves; Shares Higher Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 5% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Alexza Pharma (ALXA) Resumes, Shares Move Lower
December 21, 2012 4:15 PM ESTAlexza Pharma (NASDAQ: ALXA) shares resume trading, shares are down 6 percent late Friday.... More
Alexza Pharma (ALXA) to resume trading at 4:15pm ET
December 21, 2012 3:31 PM ESTAlexza Pharma (NASDAQ: ALXA) to resume trading at 4:15pm EST.... More
FDA Approves Alexza's (ALXA) Adusave
December 21, 2012 3:28 PM ESTAlexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food and Drug Administration (FDA) approved ADASUVE® (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE combines Alexza's proprietary Staccato® delivery system with the antipsychotic drug, loxapine. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in rapid systemic delivery and absorption of a drug. See below for Important Safety Information about ADASUVE, including Boxed Warnings.
... More
